Affymetrix Inc. has announced the publication of the MicroArray Quality Control (MAQC) study, a collaborative effort led by the FDA that included 137 scientists from private and public sector ...

Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...

Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...

Microarray technology has come of age as a powerful approach to revealing the genome and its dynamic expression through the application of gene-hybridization or gene-expression microarrays. While the ...

HOUSTON & SANTA CLARA, Calif.--(BUSINESS WIRE)--Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family ...

Affymetrix Inc. announced that the US Food and Drug Administration (FDA) has granted regulatory clearance to its GCS3000Dx (GCSDx) platform for in vitro gene expression diagnostic testing. The ...

SANTA CLARA, USA: Affymetrix, Inc. announced a co-marketing agreement naming GenoSplice, Inc. as its preferred data analysis service provider for the new GeneChip Human Transcriptome Array 2.0, a ...

Microarray giant Affymetrix has updated two of its more popular expression sets. With the release of the GeneChip ® Mouse Expression Set 430 and Rat Expression Set 230, the company now provides "the ...

The DNA marketplace is changing: the technology is maturing, whole human genome arrays, as well as those of model organisms, are beginning to make it onto the market, and researchers have more choices ...

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Richard Shippy has joined the company as its Chief Business Officer. Richard was one of the ...

An English Court of Appeals decision in November held that Affymetrix (Santa Clara, CA) has a valid license to critical DNA microarray technology developed by Oxford Gene Technology (OGT; Oxford, UK).